Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kohjin Bio CoTSE:177A -0.47%19 Receivables Turnover is 1.68 as of Mar. 2026. GuruFocus rates TSE:177A with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 845 Biotechnology companies, Kohjin Bio Co ranks better than 64.26% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kohjin Bio Co's Revenue for the
three
months ended in Mar. 2026 was 円1,147 Mil. Kohjin Bio Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was 円683 Mil.
Hence, Kohjin Bio Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.68.
Kohjin Bio Co (TSE:177A) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Kohjin Bio Co Receivables Turnover Related Terms
Kohjin Bio Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Kohjin Bio Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:177A vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Kohjin Bio Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kohjin Bio Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kohjin Bio Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Kohjin Bio Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kohjin Bio Co (TSE:177A) has a Receivables Turnover of 1.68 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kohjin Bio Co and its competitors. According to the industry distribution chart, Kohjin Bio Co ranks #302 out of 845 companies in the Biotechnology industry, placing it in the top 35.7%.
Is Kohjin Bio Co's Receivables Turnover too high?
Kohjin Bio Co's current Receivables Turnover is 1.68. The Biotechnology industry median Receivables Turnover is 5.22. Kohjin Bio Co's value of 1.68 is 67.8% below this industry median. Based on the distribution chart, Kohjin Bio Co ranks #302 out of 845 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kohjin Bio Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Kohjin Bio Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kohjin Bio Co ranks #302 out of 845 companies for Receivables Turnover. This puts Kohjin Bio Co in the upper half of its industry. The industry median Receivables Turnover is 5.22. Kohjin Bio Co's value of 1.68 is 67.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.22, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kohjin Bio Co's current Receivables Turnover of 1.68 is 67.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kohjin Bio Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kohjin Bio Co's current Receivables Turnover is 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kohjin Bio Co stock overvalued right now?
Kohjin Bio Co (TSE:177A) has a current Receivables Turnover of 1.68. The current Receivables Turnover is 1.68 and 67.8% below the Biotechnology industry median of 5.22. Kohjin Bio Co's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Kohjin Bio Co (TSE:177A), the current Receivables Turnover is 1.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kohjin Bio Co Ltd is engaged in development, manufacture and sale of culture media (growing environments used for culturing microorganisms and cells) and contract manufacturing of processed cell products. It has manufacturing and sales of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics.
19GF Score
Get the complete analysis for TSE:177A
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:177A has been successfully added to your 
